Assembly Biosciences (NASDAQ:ASMB) Share Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened

Assembly Biosciences, Inc. (NASDAQ:ASMB) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $28.97 and traded as high as $29.01. Assembly Biosciences shares last traded at $28.75, with a volume of 142,905 shares trading hands.

Analyst Upgrades and Downgrades

ASMB has been the topic of several analyst reports. Mizuho set a $40.00 price objective on shares of Assembly Biosciences and gave the company an “outperform” rating in a report on Thursday, November 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, January 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a research note on Monday, December 22nd. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $41.75.

Assembly Biosciences Price Performance

The stock has a market cap of $454.83 million, a P/E ratio of -6.00 and a beta of 1.13. The company’s 50 day simple moving average is $29.87 and its 200 day simple moving average is $28.97.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Farallon Capital Management LLC acquired a new position in Assembly Biosciences in the third quarter valued at about $31,426,000. RA Capital Management L.P. bought a new position in shares of Assembly Biosciences during the 3rd quarter valued at about $26,122,000. Commodore Capital LP acquired a new position in shares of Assembly Biosciences in the 3rd quarter valued at approximately $25,600,000. Janus Henderson Group PLC increased its stake in Assembly Biosciences by 11.3% during the 4th quarter. Janus Henderson Group PLC now owns 837,925 shares of the biopharmaceutical company’s stock worth $28,540,000 after purchasing an additional 85,299 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP bought a new stake in Assembly Biosciences during the 4th quarter worth approximately $22,625,000. 19.92% of the stock is currently owned by institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.